58509-59-4

Basic information

• Product Name: 8-(Hydroxyimino)-5,6,7,8-tetrahydroquinoline
• Synonyms: 8-(Hydroxyimino)-5,6,7,8-tetrahydroquinoline;(E)-6,7-dihydroquinolin-8(5H)-one oxiMe;6,7-Dihydro-5H-quinolin-8-one oxiMe
• CAS NO: 58509-59-4
• Molecular Formula: C₉H₁₀N₂O
• Molecular Weight: 162.1885
• Mol File: 58509-59-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 173-175 °C(Solv: benzene (71-43-2))
• Boiling Point: 353.4±21.0 °C(Predicted)
• Appearance: /
• Density: 1.27±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 10.37±0.20(Predicted)
• CAS DataBase Reference: 8-(Hydroxyimino)-5,6,7,8-tetrahydroquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 8-(Hydroxyimino)-5,6,7,8-tetrahydroquinoline(58509-59-4)
• EPA Substance Registry System: 8-(Hydroxyimino)-5,6,7,8-tetrahydroquinoline(58509-59-4)

Safety Data

• Hazardous Substances Data: 58509-59-4(Hazardous Substances Data)

Usage

Description

8-(Hydroxyimino)-5,6,7,8-tetrahydroquinoline, also known as 6,7-Dihydro-5H-quinolin-8-one Oxime, is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique structure, which includes a quinoline ring and a hydroxyimino group, making it a versatile building block for the development of new drugs and therapeutic agents.

Uses

Used in Pharmaceutical Industry:
8-(Hydroxyimino)-5,6,7,8-tetrahydroquinoline is used as an intermediate in the synthesis of 3-heterocyclylacrylamide derivatives. These derivatives act as FaBI protein inhibitors, which are essential for the development of new treatments targeting bacterial infections. By inhibiting the FaBI protein, these derivatives can potentially disrupt the bacterial cell's function and growth, leading to the eradication of the infection.
Used in Antimicrobial Applications:
As a key component in the development of FaBI protein inhibitors, 8-(Hydroxyimino)-5,6,7,8-tetrahydroquinoline plays a significant role in the fight against antibiotic-resistant bacteria. These inhibitors can be incorporated into new antimicrobial drugs, providing a much-needed alternative to traditional antibiotics and helping to combat the growing global threat of antibiotic resistance.

Upstream product

• 10500-57-9 5,6,7,8-tetrahydroquinoline 
• 28707-60-0 8-benzylidene-5,6,7,8-tetrahydroquinoline 
• 56826-69-8 5,6,7,8-tetrahydro-8-quinolinone 

Downstream Products

• 67046-21-3 O-tosyl-6,7-dihydroquinolin-8(5H)-one oxime 
• 67046-22-4 5,6,7,9-tetrahydro-8H-pyrido[2,3-b]azepin-8-one 
• 298181-83-6 5,6,7,8-tetrahydroquinolin-8-yl amine 
• 56826-69-8 5,6,7,8-tetrahydro-8-quinolinone 

Relevant articles and documents

CXCR2 ANTAGONIST

A compound as a CXCR2 antagonist and an application thereof in preparing a drug as a CXCR2 antagonist. In particular, the present invention relates to a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof.

Room-temperature copper-catalyzed arylation of dimethylamine and methylamine in neat water

The first room-temperature copper-catalyzed arylations of dimethylamine and methylamine in neat water have been developed. Using a combination of CuI and 6,7-dihydroquinolin-8(5 H)-one oxime as catalyst, dimethylamine is arylated with various aryl halides to give the corresponding products in good to excellent yields. Further, this catalysis enables the selective arylation of methylamine to afford the high yields of monoarylated methylamines as the sole products.

AMD070, a CXCR4 chemokine receptor antagonist: Practical large-scale laboratory synthesis

An efficient and convergent four-step synthetic route to the CXCR4 chemokine receptor antagonist AMD070 (1) has been developed which employs only a single chromatographic step in the entire sequence. Novel reductive amination methods have been developed for the coupling of 2 and 3 in which a dehydrative imine formation is followed by reduction with an attenuated borohydride reagent (zinc chloride and sodium borohydride). Selective extraction methods were employed to purify synthetic intermediates and remove reagents and impurities. A procedure has also been developed to isolate 1 in a pure crystalline form.